Cutter Capital Management »

Arcellx shares owned by Cutter Capital Management

Quarter-by-quarter ownership of Arcellx (ACLX) shares owned by Cutter Capital Management from 13F filings

Historical chart of Cutter Capital Management investment in Arcellx

Tip: Access up to 7 years of quarterly data

All positions including Arcellx held by Cutter Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arcellx by Cutter Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $7.4M 107k 69.55

More positions owned by Cutter Capital Management

Bristol Myers Squibb (BMY)
Gilead Sciences (GILD)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Regeneron Pharmaceuticals (REGN)
BioMarin Pharmaceutical (BMRN)
Ionis Pharmaceuticals (IONS)
Royalty Pharma Shs Class A (RPRX)
Sarepta Therapeutics (SRPT)
ACADIA Pharmaceuticals (ACAD)
Biogen Idec (BIIB)
BioCryst Pharmaceuticals (BCRX)
Halozyme Therapeutics (HALO)
Perrigo SHS (PRGO)
Exelixis (EXEL)
Avadel Pharmaceuticals SHS

View all positions for Cutter Capital Management

Top funds holding Arcellx

FMR
Perceptive Advisors
Paradigm Biocapital Advisors
NEA Management Company
Sr One Capital Management
BlackRock
Vanguard Group
Cormorant Asset Management
Suvretta Capital Management
Henderson Group
T. Rowe Price Associates
Lord, Abbett & Co
T. Rowe Price Investment Management
Geode Capital Management
Morgan Stanley

View all funds holding Arcellx